Validated high-conviction buyer — this insider’s opportunistic purchases fall in a cohort whose buys have historically preceded above-benchmark moves. How we measure this ↗
Director Agnevall Hakan buys 6,100 shares of Aptiv at $57.73 as stock trades well below its 52-week high; second open-market purchase in 36 months.
Director Agnevall Hakan purchased a material quantity of shares while the stock is trading substantially below its 52-week high, suggesting a willingness to accumulate at depressed valuations. This is his second open-market purchase in the past three years, continuing a pattern of buying rather than selling. His prior purchase at this company showed early strength but reversed course over a longer timeframe, illustrating the mixed timing outcomes typical in volatile markets. Aptiv is a profitable enterprise with steady revenue growth, but is trading at a stretched valuation multiple, meaning this director is buying into fundamentals that haven't yet justified the price he paid. The purchase size represents a significant portion of his existing holdings, indicating material personal capital commitment rather than a token gesture.
Aptiv director Agnevall Hakan bought 3,700 shares at $80.25; holdings surge 387.4% to 4,655 shares
Director Agnevall Hakan purchased 3,700 shares at $80.25 on 2025-12-12, increasing his holdings from 955 shares to 4,655 shares—a net increase of 387.4%. The purchase occurred at a price $2.83 above the current market price of $77.42, placing the transaction near the 52-week high of $87.98 and 12.0% above current levels. Aptiv faces significant operational headwinds: the latest quarter showed net income of $-355.0M against revenue of $5.2B, and annual revenue growth stands at -1.7%, indicating a loss-making position despite substantial scale. The director's substantial accumulation—tripling his prior position—comes amid this deteriorating financial performance, warranting scrutiny of the strategic rationale for accumulation at elevated valuation.
